Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: A double-blind randomized trial

Journal of Psychiatry and Neuroscience

Volumn 31, Issue 4, 2006, Pages 271-279

  Lal, Samarthji ^a,b,c,d   Thavundayil, Joseph X ^a,b   Nair, N P Vasavan ^a,b   Annable, Lawrence ^b,d   Kin, Ng M K Ng Ying ^a,b   Gabriel, Antoine ^a   Schwartz, George ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BENZATROPINE; CHLORPROMAZINE; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE PLUS METFORMIN; HALOPERIDOL; LAXATIVE; LEVOMEPROMAZINE; LIVER ENZYME; NEUROLEPTIC AGENT; NICOTINAMIDE; ORAL CONTRACEPTIVE AGENT; PROCYCLIDINE; THIAZINE DERIVATIVE; TRIHEXYPHENIDYL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGITATION; AKATHISIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFECT; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MENTAL DISEASE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; MALE; METHOTRIMEPRAZINE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33746174667     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
2. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-61.
3. Baldessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge (MA): Harvard University Press; 1985.
4. Kane JM, Honigfeld G, Singer J, et al; and the Clozaril Collaborative Study Group. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
5. Chakos M, Lieberman JA, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. A review and meta analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
6. Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract 2002;8:205-15.
7. Lieberman JA, Johns CA, Kane JM. Clozapine-induced agranulocytosis: non-cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-7.
8. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504.
9. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158:1305-13.
10. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-11.
11. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
12. Volavka J, Czobor P, Sheitman B. Clozapine, olanzapine, risperidone, and haloperidol in treatment-resistant patients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
13. Lal S, Nair NPV. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992;85:243-5.
14. Jones B, Labelle A, Fraser BA, et al. Methotrimeprazine: an alternative to clozapine in treatment-refractory schizophrenia. Clin Neuropharmacol 1992;15(Suppl 1):364.
15. Angst J, Jaenicke U, Padrutt A, et al. Ergebnisse eines doppelblindversuches von HF 1854 (8-chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e) (1,4) diazepin) im Vergleich zu levomepromazin. Pharmakopsychiatrie, Neuro-psychopharmakologie 1971;4:192-200.
16. Lal S, Nair NPV, Cecyre D, et al. Levomepromazine receptor binding profile in human brain - implications for treatment resistant schizophrenia. Acta Psychiatr Scand 1993;87:380-3.
17. Deutch AY, Moghaddam B, Innis RB, et al. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991;4:121-56.
18. Roubicek J, Major I. EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol Psychiatry 1977;12:613-33.
19. Kalinowsky LB, Hippius H. Pharmacological, convulsive and other somatic teatments in psychiatry. New York: Grunne and Stratton; 1969.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington: The Association; 1987.
21. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
22. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville (MD): US National Institute of Health, Psychopharmacology Research Branch; 1976. p. 217-22.
23. Chouinard G, Beauclair L. Antipsychotiques. In: Lalonde P, Grunberg F, editors. Manuel de psychiatrie clinique: approche bio-psycho-sociale. Montréal: Gaetan Morin; 1988. p. 1008-37.
24. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS). Rating manual. San Rafael (CA): Social and Behavioral Science Documents; 1987.
25. Honingfeld G, Klett J. The Nurses Observation Scale for Inpatient Evaluation. A new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65-71.
26. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville (MD): US National Institute of Health, Psychopharmacology Research Branch; 1976. p. 534-7.
27. Chouinard G, Annable L, Ross-Chouinard A, et al. Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 1979;40:147-52.
28. Teulié G, De Verbizier J, Poyart E, et al. Essais thérapeutiques par la lévomépromazine (7044RP) de psychoses ayant résisté aux traitements antérieurement utilisés. Ann Med Psychol (Paris) 1958;116:159-72.
29. Gurtler [ ], Soos [ ], Maumonte [ ]. Contribution à l'étude de la lévomépromazine. Ann Med Psychol (Paris) 1958;116:980-97.
30. Deschamps A, Madré J. Résultats d'un nouveau neuroleptique (lévomépromazine: 7044RP) dans les cas de démence précoce grave. Presse Med 1958;66:196-9.
31. Payne P, Verinder D. Levomepromazine in the treatment of neuroleptic-resistant psychotics. J Ment Sci 1960;106:1429-31.
32. Quinn PJG, Johnston J, Latner G, et al. A comparative controlled trial of methotrimeprazine (Veractil) in chronic schizophrenia. J Ment Sci 1960;106:160-70.
33. Hong CJ, Chen JY, Chiu HJ, et al. A double blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment refractory schizophrenia. Int Clin Psychopharmacol 1997;12:123-30.
34. Cohen BM, Benes FM, Baldesarini RJ. Atypical neuroleptics, dose-response relationships and treatment-resistant psychosis [letter]. Arch Gen Psychiatry 1989;46:381-3.
35. Lieberman RP, Van Putten T, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry 1994;151:756-9.
36. Fischer-Cornelssen KA, Ferner U. An example of European multicentre trials: multispectral analysis of clozapine. Psychopharmacol Bull 1976;12:34-9.
37. Petit M, Dollfus S. Etude critique des conditions de prescription et des critères d'évaluation d'un traitement neuroleptique dans les schizophrénies résistantes. Encephale 1992;18:447-51.